Biogen Idec Inc. has applied to the Food and Drug Administration for approval to market a new treatment for hemophilia B, the Weston biotechnology company said Friday.
Hemophilia B is a rare inherited disease that keeps patients’ blood from clotting and can cause bleeding, joint damage, and life-threatening hemorrhages. Biogen Idec said it submitted its biologics license application to the FDA recently and expects a decision some time this year. It is the first product in a class of clotting therapies the company is developing.
Biogen Idec said it is on track to submit a similar application for a drug to treat another form of the disease, hemophilia A, in the first quarter of this year.
The company, a global leader in multiple sclerosis drugs, said Thursday it was ending development of an experimental drug for Lou Gehrig’s disease after the drug proved ineffective in a late-phase clinical trial.
Robert Weisman can be reached at firstname.lastname@example.org.